Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development of a drug for vitiligo. The deal centers around TEV-‘408, an anti-IL-15 ...

Both agencies highlighted Teva's financial discipline, solid liquidity, and return to revenue growth after five years of declines, driven by strength in branded medicines and stabilization in generics ...

Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their ...

Pfizer (PFE) posted Q3 revenue of $16.65B down 5.9% as COVID products declined sharply. Paxlovid dropped 55% and Comirnaty fell 20%. Teva (TEVA) delivered its 11th consecutive quarter of growth with ...

Teva Pharmaceutical Industries TEVA.TA said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global ...

Teva Pharmaceutical Industries is launching its first global innovation platform, challenging startups to submit novel strategies to tackle seven pervasive industry hurdles that run the gamut from ...

TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a ...

From Nike to adidas and Porsche to Gap, designer and artist Sean Wotherspoon has certainly imprinted his stamp on the sneaker and lifestyle industries. The innovative collaborator has now returned to ...

Teva Pharmaceuticals announced that Fitch Ratings has upgraded its corporate credit rating from BB to BB+, maintaining a stable outlook. This upgrade reflects Teva's efforts to reduce debt, enhance ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the hybrid generics and innovative medicines giant. As part of a new bid to ...

Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and Uzedy ...